Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: Reply to the letter by Chatterjee et al “Bleeding, mortality, and antiplatelet therapy: Results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial”, American Heart Journal, January 2012, Elsevier,
DOI: 10.1016/j.ahj.2011.10.005.
You can read the full text:
Contributors
The following have contributed to this page